金嗓子控股集團有限公司 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED (根據開曼群島法律註冊成立的成員責任有限公司) 股份代號 : 06896 年度報告 2019 OLDEN THROAT CANDY - 2011 KENSE 展镇品有限公司 Golden Throat Lozenge 228节 FSC 混合產品 您自负责任的 麻辣買部的概張 F8C® C008061 13 35 GOLDEN THROAT CANDY Cden Gol Golden Throat OTC KPHI 0 le 都乐 于保健品折散な可 SC 0 0 0 11 2 登录 22.8克 目錄 2 公司簡介 3 公司資料 5 財務摘要 6 主席報告 9 釋義 13 管理層討論及分析 29 董事及高級管理層 34 董事會報告 56 企業管治報告 73 獨立核數師報告 79 綜合損益表 80 綜合全面收益表 81 綜合財務狀況表 83 綜合權益變動表 85 綜合現金流表 87 財務報表附註 164 五年財務概要 公司簡介 | --- | --- | |----------------------- ...

金嗓子控股集團有限公司 GOLDENTHROAT HOLDINGS GROUP COMPANY LIMITED ( 於 開曼群島註冊成立的有限公司) 股份代號 : 06896 0 | --- | --- | --- | --- | --- | --- | --- | |--------|---------------------------------------------------------------|----------------------|-------|-------|-------|-------| | | | | X | | | | | | | | | | | | | 都乐含 | 会杀子也 都乐 润 喝 都乐含 DULE NODO 不合成語冷食量，243 | | | | | | | 清新ł | 清凉爽 | Gold | | | | | | 登录 | . 净含量: 2 | Golden Throa Lozenge | | | | | older of the ( G FSC 混合產品 ® OTC the rident mere a seen a was beared to the str ...

Financial Performance - Revenue increased by RMB 70.1 million or 11.2% to RMB 694.2 million compared to the year ended December 31, 2017[10] - Gross profit rose by RMB 80.9 million or 18.6% to RMB 516.5 million, with a gross margin of 74.4%[10] - EBITDA increased by RMB 54.7 million or 51.5% to RMB 160.9 million compared to the previous year[10] - Profit attributable to equity holders increased by RMB 40.8 million or 66.4% to RMB 102.2 million[10] - The company's revenue for the year ended December 31, 2018, was approximately RMB 694.2 million, an increase of about RMB 70.1 million or 11.2% compared to RMB 624.1 million for the year ended December 31, 2017[60] - The group's gross profit increased to RMB 516.5 million for the year ended December 31, 2018, up approximately RMB 80.9 million or 18.6% from RMB 435.6 million for the year ended December 31, 2017, with a gross margin rising from 69.8% to 74.4%[66] - Net profit for the year ended December 31, 2018, was approximately RMB 102.2 million, an increase of about RMB 40.8 million or 66.4% from RMB 61.4 million for the year ended December 31, 2017, mainly due to increased revenue[74] Market Expansion and Product Development - The company expanded its export markets, adding six new countries, bringing the total to 42 countries[16] - New export markets developed in 2018 include Vietnam, Kazakhstan, Kyrgyzstan, Maldives, and Brazil, covering five continents[43] - The company established a flagship store on Tmall in October 2018, launching a new online product series[17] - The group plans to enhance marketing strategies for OTC products and increase market share for Golden Throat lozenges in 2019[18] - The group aims to expand both international and domestic markets through increased investment in marketing channels and promotional efforts[18] - The company has successfully exported products to 42 countries, with six new export countries added in 2018, including Vietnam and Poland[53] - The group launched an online flagship store for Golden Throat lozenges on Tmall in 2018, introducing new product variants[44] - The company aims to transform its headquarters into a food production plant and R&D center to strengthen its food business and attract more customers[58] Research and Development - A new R&D base is in the equipment installation phase, with plans for trial production by the end of 2019[17] - The company plans to invest approximately RMB 57.8 million in R&D activities, having already spent RMB 2.2 million by December 31, 2018[48] - The group is focused on achieving breakthroughs in both pharmaceutical and fast-moving consumer goods sectors in 2019[18] - The annual production capacity of Jin Sangzi throat lozenges (OTC) is expected to increase by approximately 57% following the establishment of a new production and R&D base in Guangxi, which is currently in the equipment installation and decoration phase[58] Shareholder Information and Dividends - The company proposed a final dividend of HKD 0.12 per share for the year ended December 31, 2018, subject to shareholder approval[10] - The company reported a final dividend of HKD 0.12 per share for the year ended December 31, 2018, subject to shareholder approval at the annual general meeting on May 15, 2019[98] - As of December 31, 2018, the total issued shares were 739,302,000, with significant holdings by key individuals, including 69.79% held by a trust associated with Mr. Zeng Yong[131] Governance and Compliance - The company has complied with the corporate governance code and has adopted its own governance practices to protect shareholder interests[170] - The board of directors confirmed the independence of all independent non-executive directors according to the listing rules[112] - The company emphasizes compliance with relevant laws and regulations, as well as its environmental policies, detailed in the corporate governance report[101] - The company has established appropriate arrangements for employees to raise concerns regarding financial reporting and internal controls[197] Risks and Challenges - The company is facing risks related to maintaining relationships with distributors and changes in consumer preferences, which could adversely affect its reputation and profitability[59] - The management discussion and analysis section provides insights into the group’s future business development and potential risks, located on pages 14 to 28 of the report[101] Financial Management and Audit - The company has a financial risk management policy outlined in note 34 of the financial statements[101] - Ernst & Young has been appointed as the auditor for the year ending December 31, 2018, and has not been changed since the company's listing on July 15, 2015[167] - The Audit Committee is responsible for reviewing the company's financial information before submission to the board, ensuring the independence of external auditors, and monitoring the effectiveness of the audit process[196] Related Party Transactions - The company engaged in related party transactions, including procurement of raw materials from Guangxi Changbao Biotechnology Co., Ltd. for a total of 10,130[149] - The company has a trademark licensing agreement with Peizhen Investment, which is a related party[149] - The controlling shareholders have committed not to engage in any competing business activities directly or indirectly[143]